While “Shark Tank” judge Kevin O’Leary views legal psychedelics as a once-in-a-lifetime investment opportunity, his take on cannabis is 180 degrees away.
“There isn’t a dime of institutional money here, at the sovereign level,” O’Leary told Benzinga founder and CEO Jason Raznick in a keynote discussion Tuesday at the inaugural Benzinga Psychedelics Capital Conference. “Zero. The industry, in my view, screwed itself.”
Why? The federal status of cannabis as a Schedule 1 drug.
That distinction makes cannabis difficult for institutional investors, said O’Leary, who is the chairman of O’Shares ETFs, among other pursuits.
O’Leary Says ‘Soul-Searching’ Needed In Cannabis: Transporting cannabis across state lines could trigger RICO statutes, O’Leary said.
“I don’t want to be the test case for that theory.”
Ahead of the two-day Benzinga Cannabis Capital Conference, O’Leary suggested the industry “do some soul-searching and say, ‘how do we fix this?’”
The cannabis industry needs to convince President Joe Biden to remove cannabis from the Schedule 1 list, he said, so the industry can be bifurcated into FDA-approved medicine and recreational sales.
“You’ve got a lot of tension in the space that should have been resolved early on,” he said. “Recreational cannabis is great, but it’s a nothing burger compared to what it would be if it were medicine.”
Why Canadian Cannabis Margins Are ‘Getting Crushed’: O’Leary, who was born in Montreal, gave a thumbs-down Tuesday to the Canadian cannabis space from an investment standpoint.
Referring to the province of Ontario, he said: “That business sucks. They don’t allow them to brand anything.”
The price-to-earnings ratios of Canadian cannabis stocks “have been crushed,” O’Leary said.
“There’s no differentiation. [Canadian cannabis companies] are selling it as a commodity and margins are getting crushed.”
"Shark Tank" judge Kevin O'Leary speaks Tuesday at the Benzinga Psychedelics Capital Conference in Miami Beach, Florida. Photo by Dez Smith.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.